{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:31:05Z","timestamp":1794573065305,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug overdose deaths have increased in the last decade, becoming a substantial public health priority. Mobile Addiction Treatment Units (MATU) are vans, vehicles, or portable clinics that provide low-threshold, low-barrier, community-based services for addiction treatment including opioid agonist medications. MATUs are a point of entry for care, particularly for individuals who have faced barriers to access at in-person healthcare facilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This narrative review aims to synthesize and conduct a thematic analysis of the research on implementation and outcomes of MATUs in the United States. Our study\u2019s primary objectives were threefold: 1) to evaluate MATU program reach, 2) to evaluate MATU program effectiveness, and 3) to evaluate MATU program implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified studies examining MATUs by searching electronic databases MEDLINE (Ovid), Embase (Elsevier), PsycINFO (EBSCO), and Web of Science Core Collection (Clarivate). Records were selected for full-text review if their abstract referenced any mobile modality for substance use treatments. Exclusion criteria included review articles, opinion articles, theoretical articles, abstracts, dissertations, studies conducted outside of the United States, and studies focused solely on mobile harm-reduction interventions without offering medication treatment for SUD. This review is reported per the Preferred Reporting Items of Systematic Reviews and Meta-Analyses for Scoping Review (PRISMA-ScR) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,232 articles were screened at the title and abstract level, of which 83 were assessed for full text eligibility. The 34 articles selected for inclusion were varied in methodology, and included randomized controlled trials (RCTs), observational studies, cohort studies, and mixed-methods research. The most common study locations were Baltimore, MD (10 studies), Boston, MA (5 studies), Philadelphia, PA (4 studies), and New Haven, CT (3 studies). Regarding reach, four studies were conducted during the COVID-19 pandemic. Six studies were conducted primarily in a population experiencing homelessness; two studies were conducted primarily in populations with criminal justice involvement; four studies were conducted primarily in youth or young-adult populations; three studies were conducted in rural populations. In these settings, MATUs successfully engaged vulnerable and underserved populations, delivering comprehensive care that combined harm reduction, primary care, and mental health services. These units demonstrated potential to enhance health outcomes, reduce stigma, increase treatment retention rates in marginalized populations compared to office-based programs, and tackle social determinants of health. Common challenges included patient engagement, logistical and regulatory barriers, and financial sustainability, all compounded by limited space, staffing, and resources, while homelessness, encampment removals, and the COVID-19 pandemic further disrupted care continuity (J Subst Abuse Treat 120:108149, 2021; Front Public Health 11:1154813, 2023; J Subst Use Addict Treat 159:209272, 2024; J Subst Use Addict Treat 164, 2024; Health Place 28:153\u201366, 2014; Addict Sci Clin Pract 18:71, 2023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MATUs proved to be innovative and effective in addressing OUD and related issues for vulnerable populations traditionally lacking access to care. However, ongoing efforts to overcome implementation challenges and ensure sustainable funding and resources are crucial for their continued success and expansion. Future research should focus on large-scale, quantitative studies, particularly in diverse and rural settings, to better understand their long-term impact and sustainability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00619-1","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:02:14Z","timestamp":1766570534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mobile addiction treatment units: a narrative review"],"prefix":"10.1186","volume":"20","author":[{"given":"Irving","family":"Barrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brammy","family":"Rajakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Muthupalaniappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria E.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avik","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"619_CR1","doi-asserted-by":"publisher","unstructured":"Spencer MR, Garnett MF, Mini\u00f1o AM. Drug overdose deaths in the United States, 2002-2022. NCHS Data Brief. 2024. https:\/\/doi.org\/10.15620\/cdc:135849.","DOI":"10.15620\/cdc:135849"},{"key":"619_CR2","unstructured":"U.S. overdose deaths decrease almost 27% in 2024. 2025. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2025\/20250514.htm."},{"key":"619_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169:137\u201345.","journal-title":"Ann Intern Med"},{"key":"619_CR4","doi-asserted-by":"publisher","first-page":"108717","DOI":"10.1016\/j.drugalcdep.2021.108717","volume":"224","author":"MF McLaughlin","year":"2021","unstructured":"McLaughlin MF, Li R, Carrero ND, Bain PA, Chatterjee A. Opioid use disorder treatment for people experiencing homelessness: a scoping review. Drug Alcohol Depend. 2021;224:108717.","journal-title":"Drug Alcohol Depend"},{"key":"619_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(17)31869-X","volume":"391","author":"RW Aldridge","year":"2018","unstructured":"Aldridge RW, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. Lancet. 2018;391:241\u201350.","journal-title":"Lancet"},{"key":"619_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/08897077.2018.1442899","volume":"40","author":"JR Marshall","year":"2019","unstructured":"Marshall JR, et al. Socioeconomic and geographical disparities in prescription and illicit opioid-related overdose deaths in Orange County, California, from 2010-2014. Subst Abuse. 2019;40:80\u201386.","journal-title":"Subst Abuse"},{"key":"619_CR7","doi-asserted-by":"crossref","unstructured":"Swartz N, Odayappan S, Chatterjee A, Cutler D. Impact of Medicaid expansion on inclusion of medications for opioid use disorder in homeless adults\u2019 treatment plans. J Subst Use Addict Treat. 2023;152.","DOI":"10.1016\/j.josat.2023.209059"},{"key":"619_CR8","doi-asserted-by":"publisher","first-page":"e203711","DOI":"10.1001\/jamanetworkopen.2020.3711","volume":"3","author":"WC Goedel","year":"2020","unstructured":"Goedel WC, et al. Association of Racial\/Ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020;3:e203711.","journal-title":"JAMA Netw Open"},{"key":"619_CR9","unstructured":"Waiver elimination (MAT act). 2023. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act."},{"key":"619_CR10","unstructured":"Medications for the treatment of opioid use disorder. Federal register. 2024. https:\/\/www.federalregister.gov\/documents\/2024\/02\/02\/2024-01693\/medications-for-the-treatment-of-opioid-use-disorder."},{"key":"619_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","volume":"161","author":"G Kourounis","year":"2016","unstructured":"Kourounis G, et al. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"619_CR12","doi-asserted-by":"publisher","first-page":"1407522","DOI":"10.3389\/fpubh.2024.1407522","volume":"12","author":"A Pinkhover","year":"2024","unstructured":"Pinkhover A, Celata K, Baker T, Chatterjee A, Lunze K. Mobile addiction treatment and harm reduction services as tools to address health inequities: a community case study of the Brockton neighborhood health center mobile unit. Front Public Health. 2024;12:1407522.","journal-title":"Front Public Health"},{"key":"619_CR13","doi-asserted-by":"publisher","first-page":"e220117","DOI":"10.57264\/cer-2022-0117","volume":"12","author":"CA Tschampl","year":"2023","unstructured":"Tschampl CA, et al. Protocol for the implementation of a statewide mobile addiction program. J Comp Eff Res. 2023;12:e220117.","journal-title":"J Comp Eff Res"},{"key":"619_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jsat.2013.11.002","volume":"46","author":"G Hall","year":"2014","unstructured":"Hall G, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J Subst Abuse Treat. 2014;46:511\u201315.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, et al. Prisma extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467\u201373.","journal-title":"Ann Intern Med"},{"key":"619_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.5195\/jmla.2018.513","volume":"106","author":"L Kellermeyer","year":"2018","unstructured":"Kellermeyer L, Harnke B, Knight S. Covidence and Rayyan. J Med Libr Assoc. 2018;106:580\u201383.","journal-title":"J Med Libr Assoc"},{"key":"619_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/01.XEB.0000511348.97198.8c","volume":"14","author":"K Lisy","year":"2016","unstructured":"Lisy K, Porritt K. Narrative synthesis: considerations and challenges. Int J Evid Based Healthc. 2016;14:201.","journal-title":"Int J Evid Based Healthc"},{"key":"619_CR18","doi-asserted-by":"publisher","first-page":"108149","DOI":"10.1016\/j.jsat.2020.108149","volume":"120","author":"K Wenzel","year":"2021","unstructured":"Wenzel K, Fishman M. Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with oud: an adaptation to the COVID-19 emergency. J Subst Abuse Treat. 2021;120:108149.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/ADM.0000000000000791","volume":"15","author":"M Komaromy","year":"2021","unstructured":"Komaromy M, et al. Adaptation of a system of treatment for substance use disorders during the COVID-19 pandemic. J Addict Med. 2021;15:448\u201351.","journal-title":"J Addict Med"},{"key":"619_CR20","doi-asserted-by":"publisher","first-page":"104214","DOI":"10.1016\/j.drugpo.2023.104214","volume":"121","author":"LW Suen","year":"2023","unstructured":"Suen LW, et al. \u2018Get in and get out, get on with life\u2019: patient and provider perspectives on methadone van implementation for opioid use disorder treatment. Int J Drug Policy. 2023;121:104214.","journal-title":"Int J Drug Policy"},{"key":"619_CR21","doi-asserted-by":"publisher","first-page":"1154813","DOI":"10.3389\/fpubh.2023.1154813","volume":"11","author":"MD Pepin","year":"2023","unstructured":"Pepin MD, et al. A mobile addiction service for community-based overdose prevention. Front Public Health. 2023;11:1154813.","journal-title":"Front Public Health"},{"key":"619_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1745-7599.2008.00358.x","volume":"20","author":"NH Busen","year":"2008","unstructured":"Busen NH, Engebretson JC. Facilitating risk reduction among homeless and street-involved youth. J Am Acad Nurse Pract. 2008;20:567\u201375.","journal-title":"J Am Acad Nurse Pract"},{"key":"619_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/ajad.13055","volume":"29","author":"T Iheanacho","year":"2020","unstructured":"Iheanacho T, Payne K, Tsai JM. Community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: a Pilot, feasibility study. Am J Addict. 2020;29:485\u201391.","journal-title":"Am J Addict"},{"key":"619_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1353\/hpu.2021.0119","volume":"32","author":"DR Fine","year":"2021","unstructured":"Fine DR, et al. Experience with a mobile addiction program among people experiencing homelessness. J Health Care Poor Underserved. 2021;32:1145\u201354.","journal-title":"J Health Care Poor Underserved"},{"key":"619_CR25","doi-asserted-by":"publisher","first-page":"108342","DOI":"10.1016\/j.jsat.2021.108342","volume":"127","author":"DT O\u2019Gurek","year":"2021","unstructured":"O\u2019Gurek DT, et al. Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting. J Subst Abuse Treat. 2021;127:108342.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15433710903175841","volume":"7","author":"BP Bowser","year":"2010","unstructured":"Bowser BP, Jenkins-Barnes T, Dillard-Smith C, Lockett G. Harm reduction for drug abusing ex-offenders: outcome of the California prevention and education project more project. J Evid Based Soc Work. 2010;7:15\u201329.","journal-title":"J Evid Based Soc Work"},{"key":"619_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","volume":"103","author":"N Krawczyk","year":"2019","unstructured":"Krawczyk N, et al. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J Subst Abuse Treat. 2019;103:1\u20138.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR28","unstructured":"Gibbons JB, Li W, Stuart EA, Saloner B. Simulated impact of mobile opioid treatment program units on increasing access to methadone for opioid use disorder. Health Serv Res."},{"key":"619_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0376-8716(96)01273-2","volume":"42","author":"L Greenfield","year":"1996","unstructured":"Greenfield L, Brady JV, Besteman KJ, De Smet A. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug Alcohol Depend. 1996;42:125\u201331.","journal-title":"Drug Alcohol Depend"},{"key":"619_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jsat.2019.12.008","volume":"111","author":"J Langabeer","year":"2020","unstructured":"Langabeer J, et al. Outreach to people who survive opioid overdose: linkage and retention in treatment. J Subst Abuse Treat. 2020;111:11\u201315.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR31","doi-asserted-by":"publisher","first-page":"109187","DOI":"10.1016\/j.drugalcdep.2021.109187","volume":"230","author":"R Harris","year":"2022","unstructured":"Harris R, et al. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program. Drug Alcohol Depend. 2022;230:109187.","journal-title":"Drug Alcohol Depend"},{"key":"619_CR32","doi-asserted-by":"publisher","first-page":"108553","DOI":"10.1016\/j.jsat.2021.108553","volume":"133","author":"A Rosecrans","year":"2022","unstructured":"Rosecrans A, et al. Mobile low-threshold buprenorphine integrated with infectious disease services. J Subst Abuse Treat. 2022;133:108553.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR33","first-page":"e326","volume":"16","author":"L Selitsky","year":"2022","unstructured":"Selitsky L, Buresh M, Nordeck CD, Truong A, Agus D. Higher buprenorphine dose associated with treatment retention at low-threshold clinic. J Addict Med. 2022;16:e326.","journal-title":"J Addict Med"},{"key":"619_CR34","doi-asserted-by":"publisher","first-page":"209272","DOI":"10.1016\/j.josat.2023.209272","volume":"159","author":"A Chatterjee","year":"2024","unstructured":"Chatterjee A, et al. Mobile treatment for opioid use disorder: implementation of community-based, same-day medication access interventions. J Subst Use Addict Treat. 2024;159:209272.","journal-title":"J Subst Use Addict Treat"},{"key":"619_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13722-023-00427-5","volume":"18","author":"RE Stewart","year":"2023","unstructured":"Stewart RE, et al. Mobile service delivery in response to the opioid epidemic in Philadelphia. Addict Sci Clin Pract. 2023;18:71.","journal-title":"Addict Sci Clin Pract"},{"key":"619_CR36","doi-asserted-by":"publisher","first-page":"109915","DOI":"10.1016\/j.drugalcdep.2023.109915","volume":"248","author":"M Lowenstein","year":"2023","unstructured":"Lowenstein M, et al. \u2018Come try it out. Get your foot in the door:\u2019 exploring patient perspectives on low-barrier treatment for opioid use disorder. Drug Alcohol Depend. 2023;248:109915.","journal-title":"Drug Alcohol Depend"},{"key":"619_CR37","doi-asserted-by":"crossref","unstructured":"Martinez NG, et al. \u201cI want to stay here\u201d: patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care. Drug Alcohol Depend. 2024;257.","DOI":"10.1016\/j.drugalcdep.2024.111130"},{"key":"619_CR38","doi-asserted-by":"publisher","first-page":"209262","DOI":"10.1016\/j.josat.2023.209262","volume":"159","author":"SR Peddireddy","year":"2024","unstructured":"Peddireddy SR, et al. Willingness to utilize a mobile treatment unit in five counties at the epicenter of the us rural opioid epidemic. J Subst Use Addict Treat. 2024;159:209262.","journal-title":"J Subst Use Addict Treat"},{"key":"619_CR39","doi-asserted-by":"publisher","first-page":"2306492","DOI":"10.1080\/07853890.2024.2306492","volume":"56","author":"KA Hoffman","year":"2024","unstructured":"Hoffman KA, et al. Engaging the great circle: a qualitative study of the confederated tribes of Grand Ronde\u2019s mobile medication unit. Ann Med. 2024;56:2306492.","journal-title":"Ann Med"},{"key":"619_CR40","first-page":"08","volume":"8","author":"JB Gibbons","year":"2024","unstructured":"Gibbons JB, Li W, Stuart EA, Saloner B. Simulated impact of mobile opioid treatment program units on increasing access to methadone for opioid use disorder. Health Serv Res. 2024;8:08.","journal-title":"Health Serv Res"},{"key":"619_CR41","doi-asserted-by":"crossref","unstructured":"Davis MT, et al. Mobile clinics for opioid use disorders: what they do and how they do it. A qualitative analysis. J Subst Use Addict Treat. 2024;164.","DOI":"10.1016\/j.josat.2024.209428"},{"key":"619_CR42","first-page":"01","volume":"1","author":"KR Page","year":"2024","unstructured":"Page KR, et al. Integrated care van delivery of evidence-based services for people who inject drugs: a cluster-randomized trial. Addiction. 2024;1:01.","journal-title":"Addiction"},{"key":"619_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13722-022-00299-1","volume":"17","author":"BE Biondi","year":"2022","unstructured":"Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addict Sci Clin Pract. 2022;17:15.","journal-title":"Addict Sci Clin Pract"},{"key":"619_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s11606-020-06448-z","volume":"37","author":"AJ Kennedy","year":"2022","unstructured":"Kennedy AJ, et al. Factors associated with long-term retention in buprenorphine-based addiction treatment programs: a systematic review. J Gen Intern Med. 2022;37:332\u201340.","journal-title":"J Gen Intern Med"},{"key":"619_CR45","doi-asserted-by":"publisher","DOI":"10.14288\/1.0417296","volume-title":"Characterization of overdose survivors and their outcomes in opioid agonist treatment : findings from a pragmatic, pan-Canadian, randomized control trial","author":"H Crepeault","year":"2022","unstructured":"Crepeault H. Characterization of overdose survivors and their outcomes in opioid agonist treatment : findings from a pragmatic, pan-Canadian, randomized control trial. University of British Columbia; 2022. https:\/\/doi.org\/10.14288\/1.0417296."},{"key":"619_CR46","doi-asserted-by":"publisher","first-page":"e210477","DOI":"10.1001\/jamanetworkopen.2021.0477","volume":"4","author":"DR Fine","year":"2021","unstructured":"Fine DR, et al. Office-based addiction treatment retention and mortality among people experiencing homelessness. JAMA Netw Open. 2021;4:e210477.","journal-title":"JAMA Netw Open"},{"key":"619_CR47","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/10826084.2023.2212279","volume":"58","author":"DR Fine","year":"2023","unstructured":"Fine DR, et al. Health care utilization among homeless-experienced adults who were seen by a mobile addiction health clinic in Boston, Massachusetts: a quasi-experimental study. Subst Use Misuse. 2023;58:1115\u201320.","journal-title":"Subst Use Misuse"},{"key":"619_CR48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fpubh.2020.00501","volume":"8","author":"C Regis","year":"2020","unstructured":"Regis C, et al. Community care in reach: mobilizing harm reduction and addiction treatment services for vulnerable populations. Front Public Health. 2020;8:501.","journal-title":"Front Public Health"},{"key":"619_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0740-5472(02)00343-4","volume":"24","author":"I Kuo","year":"2003","unstructured":"Kuo I, et al. Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance. J Subst Abuse Treat. 2003;24:67\u201374.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR50","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1081\/JA-120004184","volume":"37","author":"A Rosenblum","year":"2002","unstructured":"Rosenblum A, Nuttbrock L, McQuistion H, Magura S, Joseph H. Medical outreach to homeless substance users in New York City: preliminary results. Subst Use Misuse. 2002;37:1269\u201373.","journal-title":"Subst Use Misuse"},{"key":"619_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1353\/hpu.2010.0831","volume":"14","author":"L Nuttbrock","year":"2003","unstructured":"Nuttbrock L, McQuistion H, Rosenblum A, Magura S. Broadening perspectives on mobile medical outreach to homeless people. J Health Care Poor Underserved. 2003;14:5\u201316.","journal-title":"J Health Care Poor Underserved"},{"key":"619_CR52","doi-asserted-by":"crossref","unstructured":"Noyes E, et al. Harm reduction for adolescents and young adults during the COVID-19 pandemic: a case study of community care in reach. Public Health Rep Wash DC 1974. 2021;136:301\u201308.","DOI":"10.1177\/0033354921999396"},{"key":"619_CR53","doi-asserted-by":"publisher","first-page":"108752","DOI":"10.1016\/j.jsat.2022.108752","volume":"138","author":"N Swartz","year":"2022","unstructured":"Swartz N, Adnan T, Perea F, Baggett TP, Chatterjee A. \u2018Sick and tired of being sick and tired\u2019: exploring initiation of medications for opioid use disorder among people experiencing homelessness. J Subst Abuse Treat. 2022;138:108752.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR54","doi-asserted-by":"publisher","first-page":"117822182211038","DOI":"10.1177\/11782218221103859","volume":"16","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, et al. \u2018You\u2019re not supposed to be on it forever\u2019: medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst Abuse Res Treat. 2022;16:11782218221103859.","journal-title":"Subst Abuse Res Treat"},{"key":"619_CR55","doi-asserted-by":"publisher","first-page":"209270","DOI":"10.1016\/j.josat.2023.209270","volume":"159","author":"K McLean","year":"2024","unstructured":"McLean K, Murphy J, Kruis N. \u2018I think we\u2019re getting better but we\u2019re still not there\u2019: provider-based stigma and perceived barriers to care for people who use opioids (PWUO). J Subst Use Addict Treat. 2024;159:209270.","journal-title":"J Subst Use Addict Treat"},{"key":"619_CR56","doi-asserted-by":"publisher","first-page":"104329","DOI":"10.1016\/j.drugpo.2024.104329","volume":"124","author":"AL Fixler","year":"2024","unstructured":"Fixler AL, Jacobs LA, Jones DB, Arnold A, Underwood EE. There goes the neighborhood? The public safety enhancing effects of a mobile harm reduction intervention. Int J Drug Policy. 2024;124:104329.","journal-title":"Int J Drug Policy"},{"key":"619_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.healthplace.2014.04.008","volume":"28","author":"BA Gibson","year":"2014","unstructured":"Gibson BA, Ghosh D, Morano JP, Altice FL. Accessibility and utilization patterns of a mobile medical clinic among vulnerable populations. Health Place. 2014;28:153\u201366.","journal-title":"Health Place"},{"key":"619_CR58","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1353\/hpu.2017.0065","volume":"28","author":"BA Gibson","year":"2017","unstructured":"Gibson BA, et al. Innovative program delivery and determinants of frequent visitation to a mobile medical clinic in an urban setting. J Health Care Poor Underserved. 2017;28:643\u201362.","journal-title":"J Health Care Poor Underserved"},{"key":"619_CR59","volume-title":"Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for opioid use disorder save lives","author":"National Academies of Sciences","year":"2019","unstructured":"National Academies of Sciences. Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for opioid use disorder save lives. Washington (DC): National Academies Press (US); 2019."},{"key":"619_CR60","doi-asserted-by":"publisher","first-page":"e227028","DOI":"10.1001\/jamanetworkopen.2022.7028","volume":"5","author":"PJ Joudrey","year":"2022","unstructured":"Joudrey PJ, et al. Assessment of community-level vulnerability and access to medications for opioid use disorder. JAMA Netw Open. 2022;5:e227028.","journal-title":"JAMA Netw Open"},{"key":"619_CR61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF02287327","volume":"32","author":"D Deck","year":"2005","unstructured":"Deck D, Carlson MJ. Retention in publicly funded methadone maintenance treatment in two Western States. J Behav Health Serv Res. 2005;32:43\u201360.","journal-title":"J Behav Health Serv Res"},{"key":"619_CR62","unstructured":"Why HEAL? | NIH HEAL initiative. 2023. https:\/\/heal.nih.gov\/about\/why-heal."},{"key":"619_CR63","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12954-022-00721-6","volume":"19","author":"TS Bartholomew","year":"2022","unstructured":"Bartholomew TS, et al. \u2018We want everything in a one-stop shop\u2019: acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs. Harm Reduct J. 2022;19:133.","journal-title":"Harm Reduct J"},{"key":"619_CR64","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/07853890.2021.2022188","volume":"54","author":"SM Grieb","year":"2022","unstructured":"Grieb SM, et al. Awareness, perception and utilization of a mobile health clinic by people who use drugs. Ann Med. 2022;54:138\u201349.","journal-title":"Ann Med"},{"key":"619_CR65","doi-asserted-by":"publisher","first-page":"209054","DOI":"10.1016\/j.josat.2023.209054","volume":"150","author":"SE Messmer","year":"2023","unstructured":"Messmer SE, et al. Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago. J Subst Use Addict Treat. 2023;150:209054.","journal-title":"J Subst Use Addict Treat"},{"key":"619_CR66","doi-asserted-by":"publisher","first-page":"108377","DOI":"10.1016\/j.jsat.2021.108377","volume":"129","author":"RE Stewart","year":"2021","unstructured":"Stewart RE, et al. Transporting to treatment: evaluating the effectiveness of a mobile engagement unit. J Subst Abuse Treat. 2021;129:108377.","journal-title":"J Subst Abuse Treat"},{"key":"619_CR67","unstructured":"National Academies of Sciences E, et al. The history of methadone and barriers to access for different populations. In: Methadone treatment for opioid use disorder: improving access through regulatory and legal change: Proceedings of a Workshop. National Academies Press (US); 2022."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00619-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:02:09Z","timestamp":1766574129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-025-00619-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00619-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}